Enrique Esteve Valverde, MD, PhD

🗣️ Olga Pané: "La IA és extraordinàriament efectiva i diagnostica amb una precisió igual o superior a la dels professionals" ❌ La consellera de @salutcat ha de rectificar de manera pública i immediata, o deixar el càrrec.

Por mi parte, gracias a @csapg_ y Dr A. Culla por confiar en mí y apostar por impulsar la investigación en el área de las enfermedades autoinmunes y sistémicas. 🙏✨ Con muchas ganas de seguir creciendo juntos y aportando a la ciencia y a l@s pacientes. 💡💚 #teamwork #garraf

Wrapping up #ICAPA2025 in Kyoto with great joy and pride. ✨ Our autoimmune & systemic diseases team @VHIR @vallhebron presented 5 works, with one awarded 🏆. Now looking ahead to the next meetings, with our eyes set on #Barcelona2028. 🇯🇵➡️🇪🇸

Termina #ICAPA2025 en Kioto con satisfacción por el trabajo realizado. ✨ Nuestro grupo de enfermedades autoinmunes y sistémicas @VHIR_ @vallhebron ha presentado 5 trabajos, uno de ellos premiado 🏆. Ahora, a preparar las próximas citas, con mirada puesta en #Barcelona2028.🇯🇵➡️🇪🇸

What an announcement at the closing of the World Congress on APS from Prof. Cervera @hospitalclinic! 🌍✨ The next World Congress on #APS will be in Barcelona 2028! Looking forward to contributing as much as possible! #icapa2028 Congrats Prof. Cervera & Prof. @gerardespinosa5

Vaya anuncio nos acaba de hacer en el cierre del congreso mundial de SAF el prof. Ricard Cervera de @hospitalclinic !Próximo congreso mundial de #saf en Barcelona 2028! Con muchas ganas de aportar el máximo! #icapa2025 #icapa2028 felicidades Prof Cervera y Prof @gerardespinosa5

📚 Reference: Žigon P, Lakota K, Čučnik S, Rotar Ž, Gavasso S, Gobbo G, Simioni P, Hoxha A. Clinical relevance of isolated anti-phosphatidylserine/prothrombin antibody positivity. 18th International Congress on Antiphospholipid Antibodies (ICAPA 2025); Sept 10–13, 2025; Kyoto.

⚖️ Evidence is promising, but every case must be individualized. 👉 Most importantly: patients should be assessed by experts. 💡 Science moves forward with prudence — that’s how clinical practice transforms.

🔬 An “overlooked” antibody is gaining strength in antiphospholipid syndrome (APS): aPS/PT. Could it change the way we diagnose and manage APS? 🧵👇

𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗼𝗳 𝗔𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗧𝗲𝘀𝘁𝗼𝘀𝘁𝗲𝗿𝗼𝗻𝗲 Many of the benefits and some of the risks of testosterone treatment are mediated by the mechanisms through which testosterone acts. Testosterone has anabolic effects on muscle (panel A) and bone (panel B) and stimulates erythropoiesis (panel C) through androgen receptor–mediated mechanisms. Nongenomic mechanisms of action increase penile blood flow and improve erectile function (panel D). The effects of testosterone on sexual desire and bone are mediated largely through its conversion to 17β-estradiol. Testosterone is also converted to dihydrotestosterone (DHT), which stimulates prostate growth and has additional anabolic effects on muscle and bone. Testosterone and DHT increase penile blood flow and erections through a rapid increase in the production of nitric oxide, which is endothelium-dependent, as well as through inhibition of voltage-operated l-type calcium channels, activation of potassium channels on smooth muscle, or both mechanisms, which are endothelium-independent (panel D). A metabolite of DHT, 5α-androstane-3α,17β-diol, which is a ligand for the γ-aminobutyric acid receptor, has been linked to mood and affect. Learn more in the Review Article “Testosterone Treatment in Middle-Aged and Older Men with Hypogonadism” by Shalender Bhasin, MB, BS, and Peter J. Snyder, MD, from @BrighamWomens, @harvardmed, and @PennMedicine: nej.md/4ooeFo7

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS - Developed by the International VEXAS Working Group Expert Panel Figure: A practical treatment algorithm for clinical management of VEXAS syndrome based on current available evidence

🧵 Red Eye in Rheumatology — When It’s Not “Just Conjunctivitis” In rheumatology, a red eye can mean systemic inflammation, vasculitis, or a vision-threatening flare. Here’s how to tell benign from dangerous — fast. 👇 @IhabFathiSulima @DrAkhilX @CelestinoGutirr #MedTwitter #NEETPG

A table summarizing common coagulation tests, their measures, conditions under which they are prolonged or normal, and the interpretation of results for likely diagnoses. anesthguide.com/topic/coagulat…

New content online: Platelets as drivers of immunothrombosis in rheumatic diseases bit.ly/4nAhTED

New #EULAR clasificstion for Anti-Synthetase Syndrome [ASyS] #Rheumatology #MedTwitter #Myositis

🔴 NEW EULAR recommendations for #SLE with #kidney involvment (2025)! ➡️ early biopsy ➡️ early combination ➡️ non immune treatment #EULAR2025

🧪 New #EULAR2025 poster by @VHIR_ elevated cut-offs (99th percentile) fail to harmonize antiphospholipid antibody testing across platforms. Major discrepancies found in aCL and aß2GPI IgG levels, impacting diagnosis and patient eligibility. Standardization still urgently needed

🧬New #EULAR2025 poster by Systemic diseases group in @VHIR_ applying 2023 ACR/EULAR criteria to EUROAPS registry excludes 71.8% of previously eligible OAPS patients due to isolated pregnancy losses and isolated IgM positivity. Urgent need to align criteria with real-world data.